Florence Chaverneff, PhD

Editor https://www.neurologyadvisor.com

Florence Chaverneff, PhD, is the editor for Clinical Pain Advisor at Haymarket Media. A neuroscientist by training, Florence conducted basic research investigating mechanisms underlying Alzheimer disease, schizophrenia, and multiple sclerosis, and acquired additional experience in stem cell biology.

All articles by Florence Chaverneff, PhD

ACTRIMS Forum 2020

Efficacy of Ofatumumab Greater than Teriflunomide in Early Relapsing MS

Florence Chaverneff, PhD

September 12, 2020

Ofatumumab was found to have greater efficacy than teriflunomide for the treatment of patients with newly diagnosed relapsing multiple sclerosis.

Migraine and Headache

Weight Loss Associated With Improvements in Migraine in Obese Individuals

Florence Chaverneff, PhD

April 8, 2019

Individuals with migraine who are obese may have reduced migraine frequency, lower pain intensity, shorter attack duration, and improved disability after losing weight.

Migraine and Headache

Weight Loss Associated With Improvements in Migraine in Obese Individuals

Florence Chaverneff, PhD

March 27, 2019

Individuals with migraine who are obese may have reduced migraine frequency, lower pain intensity, shorter attack duration, and improved disability after losing weight.

Neuropathy

Transcutaneous Electrical Nerve Stimulation Reduces Pain, Fatigue in Fibromyalgia

Florence Chaverneff, PhD

November 2, 2018

Transcutaneous electrical nerve stimulation administered during physical activity may effectively alleviate fibromyalgia-associated pain, fatigue, and disease impact in women.

Pain

Benefits of a Pain and Stress Management Program for the Management of Chronic Pain

Florence Chaverneff, PhD

October 31, 2018

A “Pain and Stress Management” program for the management of chronic pain, was found to be effective in alleviating pain, diminishing stress, promoting self-management of pain, and ameliorating general well-being.

woman with a headache being offered water

AHS 2018

Eptinezumab May Provide Fast, Effective Reduction of Monthly Migraine Days

Florence Chaverneff, PhD

July 1, 2018

Eptinezumab has shown 100% bioavailability when administered intravenously.

AHS 2018

Fremanezumab May Help Reduce Medication Overuse in Chronic Migraine

Florence Chaverneff, PhD

July 1, 2018

Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.

AHS 2018

Chronic Migraine Associated With Age-Related Changes in Cortical Thickness

Florence Chaverneff, PhD

June 30, 2018

Individuals with chronic migraine may present with age-related changes in cortical thickness.

AAN 2018 Coverage

Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine

Florence Chaverneff, PhD

April 25, 2018

Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.

AAN 2018 Coverage

Eptinezumab for Frequent Episodic Migraine: Results of Phase 3 PROMISE-1 Study

Florence Chaverneff, PhD

April 24, 2018

Eptinezumab, a humanized monoclonal antibody specific to calcitonin gene-related peptide, may be an effective prophylactic for individuals with frequent episodic migraines.

Next post in AAN 2018 Coverage